Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.51 |
| ▸ | YARS1 | P54577 | 2/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 2/20 | 0.49 |
| ▸ | CSK | P41240 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30708085 | 1.00 | SLC7A5 (0.62) | SLC7A5TAAR1SLC6A2LNPEPERAP2 | |
| SCHEMBL2017291 | 1.00 | SLC7A5 (0.62) | SLC7A5TAAR1SLC6A2LNPEPERAP2 | |
| Hydrochloric Acid SCHEMBL5188417 | 0.98 | SLC7A5 (0.61) | SLC7A5TAAR1SLC6A2LNPEPERAP2 | |
| Hydrochloric Acid SCHEMBL5187514 | 0.98 | SLC7A5 (0.61) | SLC7A5TAAR1SLC6A2LNPEPERAP2 | |
| Hydrochloric Acid SCHEMBL10349711 | 0.98 | SLC7A5 (0.61) | SLC7A5TAAR1SLC6A2LNPEPERAP2 | |
| SCHEMBL7275549 | 0.86 | CSK (0.49) | SLC7A5LNPEPERAP2CSK | |
| SCHEMBL21410883 | 0.86 | CSK (0.49) | SLC7A5CSK | |
| SCHEMBL21410884 | 0.86 | CSK (0.49) | SLC7A5CSK | |
| SCHEMBL7275544 | 0.86 | CSK (0.49) | SLC7A5LNPEPERAP2CSK | |
| SCHEMBL12323415 | 0.86 | CSK (0.49) | SLC7A5CSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2895482-A1 | HIV PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-07-22 | — | — | EP | claimed |
| US-20140378668-A1 | Tyrosine Bioconjugation through Aqueous Ene-Like Reactions | SCRIPPS RESEARCH INST (US) | 2014-12-25 | — | — | US | claimed |
| WO-2014043019-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-03-20 | — | — | WO | claimed |
| US-20120289682-A1 | Tyrosine Bioconjugation through Aqueous Ene-Like Reactions | THE SCRIPPS RESEARCH INSTITUTE | 2012-11-15 | — | — | US | claimed |
| EP-2515914-A1 | TYROSINE BIOCONJUGATION THROUGH AQUEOUS ENE-LIKE REACTIONS | The Scripps Research Institute (US) | 2012-10-31 | — | — | EP | claimed |
| WO-2011079315-A1 | TYROSINE BIOCONJUGATION THROUGH AQUEOUS ENE-LIKE REACTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-06-30 | — | — | WO | claimed |
| US-6486193-B2 | ANTIARTHRITIC AGENTS; ANTIINFLAMMATORY AGENTS | AVENTIS PHARMACEUTICALS INC. | 2002-11-26 | — | — | US | claimed |
| US-20020037859-A1 | 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases | AVENTISUB INC. | 2002-03-28 | — | — | US | claimed |
| EP-0126974-B1 | CARBOXYALKYL PEPTIDE DERIVATIVES | G.D. Searle & Co. (US) | 1988-06-15 | — | — | EP | claimed |
| EP-4494698-A2 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2025-01-22 | — | — | EP | disclosed |
| EP-3661922-B1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-23 | — | — | EP | disclosed |
| WO-2024147125-A1 | CYCLOBUTYL-SUBSTITUTED PHENOXY-DIOXETANES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-07-11 | — | — | WO | disclosed |
| US-20240199602-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-20 | — | — | US | disclosed |
| WO-2024081302-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF AMINO ACID SIDE CHAINS USING CYCLIC IMINE MANNICH ELECTROPHILES | PURDUE RESEARCH FOUNDATION (US) | 2024-04-18 | — | — | WO | disclosed |
| EP-0498665-A1 | Hydroxamic acids derivatives, process for their preparation and use thereof | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1992-08-12 | — | — | EP | disclosed |
| EP-0159396-B1 | CARBOXYALKYL PEPTIDE DERIVATIVES | G.D. Searle & Co. (US) | 1990-06-27 | — | — | EP | disclosed |
| US-4681966-A | ANTIARTHRITIC AGENTS | G. D. SEARLE & CO. (US) | 1987-07-21 | — | — | US | disclosed |
| EP-0185380-A2 | Thiol based collagenase inhibitors | G.D. Searle & Co. (US) | 1986-06-25 | — | — | EP | disclosed |
| US-4595700-A | Thiol based collagenase inhibitors | G. D. SEARLE & CO. (US) | 1986-06-17 | — | — | US | disclosed |
| US-4276288-A | Dehydrooligopeptides, their production and their medicinal use | TROPONWERKE GMBH & CO., KG (DE) | 1981-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199602-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | SLC7A5 3109/4885TAAR1 3136/4885SLC6A2 3326/4885 |
| US-20140378668-A1 | Tyrosine Bioconjugation through Aqueous Ene-Like Reactions | TYR, DNPEP, TH | SLC7A5 580/4885TAAR1 2026/4885SLC6A2 1848/4885 |
| US-20120289682-A1 | Tyrosine Bioconjugation through Aqueous Ene-Like Reactions | TYR, DNPEP, TH | SLC7A5 580/4885TAAR1 2026/4885SLC6A2 1848/4885 |
| US-20020037859-A1 | 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases | MMP3, MMP1, MMP9 | SLC7A5 2741/4885TAAR1 3584/4885SLC6A2 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.